IKT Inhibikase Therapeutics, Inc.

Nasdaq inhibikase.com


$ 1.60 $ -0.02 (-1.23 %)    

Wednesday, 15-Oct-2025 15:59:50 EDT
QQQ $ 603.56 $ 4.22 (0.71 %)
DIA $ 462.77 $ 0.00 (0 %)
SPY $ 665.96 $ 2.94 (0.44 %)
TLT $ 90.71 $ -0.20 (-0.22 %)
GLD $ 387.02 $ 6.60 (1.73 %)
$ 1.6
$ 1.63
$ 1.50 x 500
$ 1.68 x 28,610
$ 1.55 - $ 1.67
$ 1.42 - $ 4.20
128,862
na
119.23M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inhibikase-therapeutics-to-initiate-phase-2b-study-of-ikt-001-in-pah-in-h2-2025

-SEC Filing

 inhibikase-therapeutics-q2-eps-011-misses-009-estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate...

 inhibikase-therapeutics-files-for-mixed-shelf-of-up-to-300m

https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm

 inhibikase-therapeutics-q1-eps-015-misses-012-estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate...

 hc-wainwright--co-reiterates-neutral-on-inhibikase-therapeuticsto-neutral

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from Neutral to Neutral.

 inhibikase-therapeutics-fy-2024-gaap-eps-116-misses-090-estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate...

 hc-wainwright--co-downgrades-inhibikase-therapeutics-to-neutral

HC Wainwright & Co. analyst Edward White downgrades Inhibikase Therapeutics (NASDAQ:IKT) from Buy to Neutral.

 inhibikase-therapeutics-q3-2024-gaap-eps-065-misses-037-estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate...

 jefferies-initiates-coverage-on-inhibikase-therapeutics-with-buy-rating-announces-price-target-of-8

Jefferies analyst Dennis Ding initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION